Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director February 11, 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis February 10, 2026
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity February 6, 2026
Roundtable Healthcare Partners Invests in Colorescience, a Premium Skincare and Sun Protection Brand February 3, 2026
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites February 2, 2026
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad January 21, 2026
